Efficacy and Safety of Less Frequent/Lower Intensity Dosing of Talquetamab in Patients with Relapsed/Refractory Multiple Myeloma: Results from the Phase 1/2 MonumenTAL-1 Study

被引：17

作者：

Chari, Ajai ^{[1
]}

Oriol, Albert ^{[2
,3
]}

Krishnan, Amrita ^{[4
]}

Martinez Chamorro, Maria Del Carmen ^{[5
]}

Costa, Luciano ^{[6
]}

Mateos, Maria Victoria ^{[7
]}

Minnema, Monique C. ^{[8
]}

Campagna, Michela ^{[9
]}

Masterson, Tara J. ^{[10
]}

Hilder, Brandi W. ^{[10
]}

Tolbert, Jaszianne ^{[11
]}

Renaud, Thomas ^{[11
]}

Smit, M. Damiette ^{[12
]}

Ramanjulu, Swarna ^{[10
]}

Otero, Paula Rodriguez ^{[13
]}

机构：

[1] Mt Sinai Sch Med, New York, NY USA

[2] Hosp Germans Trias i Pujol, Inst Catala Oncol, Barcelona, Spain

[3] Hosp Germans Trias i Pujol, Inst Josep Carreras, Barcelona, Spain

[4] City Hope Natl Med Ctr, Judy & Bernard Briskin Ctr Multiple Myeloma Res, Irvine, CA USA

[5] Univ Hosp Quironsalud, Pozuelo De Alarcon, Madrid, Spain

[6] Univ Alabama Birmingham, Vestavia, AL USA

[7] Univ Hosp Salamanca IBSAL CIC CIBERONC, Salamanca, Spain

[8] Univ Med Ctr Utrecht, Utrecht, Netherlands

[9] Janssen Res & Dev, Madrid, Spain

[10] Janssen Res & Dev, Spring House, PA USA

[11] Janssen Res & Dev, Raritan, NJ USA

[12] Janssen Biol BV, Leiden, Netherlands

[13] Clin Univ Navarra, Pamplona, Spain

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-181228

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[1] Mechanisms of Resistance and Relapse with Talquetamab in Patients with Relapsed/Refractory Multiple Myeloma from the Phase 1/2 MonumenTAL-1 Study
Vishwamitra, Deeksha
Skerget, Sheri
Cortes, Diana
Lau, Onsay
Davis, Cuc
Renaud, Thomas
Tolbert, Jaszianne
Hilder, Brandi W.
Masterson, Tara J.
Campagna, Michela
Heuck, Christoph
Chari, Ajai
van de Donk, Niels W. C. J.
Verona, Raluca
BLOOD, 2023, 142
[2] Efficacy and Safety of Talquetamab, a GPRC5DxCD3 Bispecific Antibody, in Japanese Patients with Relapsed/Refractory Multiple Myeloma from the Phase 1/2 Monumental-1 Study
Ito, Shigeki
Kuroda, Yoshiaki
Sunami, Kazutaka
Matsue, Kosei
Imada, Kazunori
Tamura, Hideto
Takamoto, Mikihiro
Yamazaki, Hiroshi
Fujikawa, Ei
Pei, Lixia
Masterson, Tara J.
Campagna, Michela
Lau, Bonnie W.
Takamatsu, Yasushi
BLOOD, 2024, 144 : 7011 - 7012
[3] Prophylactic Tocilizumab to Mitigate Cytokine Release Syndrome in Patients Receiving Talquetamab for Relapsed/Refractory Multiple Myeloma: Results From the Phase 1/2 MonumenTAL-1 Study
Schinke, Carolina
Vij, Ravi
Jagannath, Sundar
Sanchez, Larysa
Pianko, Matthew
Jakubowiak, Andrzej
Masterson, Tara J.
Campagna, Michela
Zhang, Guoqiang
Gray, Kathleen
Renaud, Thomas
Lau, Bonnie W.
Morgan, Gareth
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S86 - S86
[4] Long-Term Efficacy and Safety Results From the Phase 1/2 MonumenTAL-1 Study of Talquetamab, a GPRC5DxCD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma
Ye, Jing Christine
Schinke, Carolina
Touzeau, Cyrille
Minnema, Monique
van de Donk, Niels
Rodriguez-Otero, Paula
Mateos Manteca, Maria-Victoria
Rasche, Leo
Vishwamitra, Deeksha
Singh, Indrajeet
Qin, Xiang
Campagna, Michela
Hilder, Brandi
Tolbert, Jaszianne
Renaud, Thomas
Heuck, Christoph
Kane, Colleen
Chari, Ajai
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S99 - S99
[5] Plain language summary of the MonumenTAL-1 study of talquetamab in people with relapsed or refractory multiple myeloma
不详
FUTURE ONCOLOGY, 2023, 19 (27) : 1823 - 1840
[6] Clinical Outcomes of Subsequent Therapies in Patients with Relapsed/Refractory Multiple Myeloma Following Talquetamab Treatment: Analyses from the Phase 1/2 MonumenTAL-1 Study
Sanchez, Larysa
Schinke, Carolina
Krishnan, Amrita
Berdeja, Jesus G.
de Donk, Niels W. C. J. van
Mateos, Maria Victoria
Chari, Ajai
Parekh, Samir
Mouhieddine, Tarek H.
Jagannath, Sundar
Bahlis, Nizar J.
Touzeau, Cyrille
Oriol, Albert
San-Miguel, Jesus
Otero, Paula Rodriguez
Minnema, Monique C.
Campagna, Michela
Masterson, Tara J.
Hilder, Brandi W.
Tolbert, Jaszianne
Renaud, Thomas
Gray, Kathleen
Smit, Damiette
Heuck, Christoph
Rasche, Leo
BLOOD, 2023, 142
[7] Long-term Efficacy and Safety Results From the Phase 1/2 MonumenTAL-1 Study of Talquetamab, a GPRC5DxCD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
Rasche, Leo
Schinke, Carolina
Touzeau, Cyrille
Minnema, Monique C.
van de Donk, Niels W. C. J.
Rodriguez-Otero, Paula
Mateos, Maria-Victoria
Ye, Jing Christine
Vishwamitra, Deeksha
Singh, Indrajeet
Qin, Xiang
Campagna, Michela
Masterson, Tara
Hilder, Brandi W.
Tolbert, Jaszianne
Renaud, Thomas
Heuck, Christoph
Kane, Colleen
Chari, Ajai
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S561 - S562
[8] Talquetamab plus Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Safety and Preliminary Efficacy Results from the Phase 1b MonumenTAL-2 Study
Matous, Jeffrey
Biran, Noa
Perrot, Aurore
Berdeja, Jesus G.
Dorritie, Kathleen
Van Elssen, Janine
Searle, Emma
Touzeau, Cyrille
Anguille, Sebastien
Vishwamitra, Deeksha
Nguyen, Ashley
Ghosh, Debopriya
Shearin, Elizabeth
Thornton, Katherine
Smit, Damiette
Quach, Hang
BLOOD, 2023, 142
[9] Cytokine Release Syndrome in Patients Receiving Alternative Step-Up Doses of Talquetamab for Relapsed/Refractory Multiple Myeloma: Results from the Phase 1/2 MonumenTAL-1 Study
Morillo, Daniel
Chamorro, Carmen Martinez
Mateos Manteca, Maria-Victoria
Costa, Luciano
Minnema, Monique
Sanchez, Larysa
Hilder, Brandi
Singh, Indrajeet
Gong, Joy
Lau, Bonnie W.
Renaud, Thomas
Rodriguez-Otero, Paula
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S74 - S75
[10] Symptoms, Functioning, and Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Talquetamab: Updated PatientReported Outcomes from the Phase 1/2 MonumenTAL-1 Study
Schinke, Carolina
Touzeau, Cyrille
Oriol, Albert
Mateos, Maria-Victoria
Stevens, Don A.
Rasche, Leo
Qin, Xiang
Kato, Kelly
Ming, Timothy
Katz, Eva G.
Gries, Katharine S.
Campagna, Michela
Masterson, Tara J.
Hilder, Brandi W.
Tolbert, Jaszianne
Renaud, Thomas
Heuck, Christoph
Moreau, Philippe
San-Miguel, Jesus
Rodriguez Otero, Paula
Chari, Ajai
BLOOD, 2023, 142

← 1 2 3 4 5 →